Sporozoite immunization: innovative translational science to support the fight against malaria
暂无分享,去创建一个
Joana C. Silva | S. Hoffman | A. Dicko | J. Kublin | A. Vaughan | S. Kappe | A. Olotu | B. Mordmüller | P. Kremsner | S. Abdulla | M. Oneko | C. Janse | S. Sirima | R. Sauerwein | K. Lyke | B. Franke-Fayard | P. Billingsley | S. Jongo | T. Richie | C. Daubenberger | B. Sim | I. Sagara | P. Duffy | M. Roestenberg | M. McCall | J. Epstein | M. Laurens | S. Healy | Tooba Murshedkar | Natasha Kc | M. Sissoko | Y. Abebe | B. K. Lee Sim | S. Murphy | A. Kreidenweiss | L. Steinhardt | M. Kapulu | Halimatou Diawara | D. Dolberg | S. T. Agnandji | L. Church | S. Chakravarty | Mei-Chun Chen | Eric R. James | Marcel Tanner | Natasha Kc | David M Cook | María-Silvia A López Mikue | Marcel Tanner | Said Jongo | María-Silvia A. López Mikue
[1] G. E. Potter,et al. A randomized controlled trial showing safety and efficacy of a whole sporozoite vaccine against endemic malaria , 2022, Science Translational Medicine.
[2] S. Hoffman,et al. In vitro production of infectious Plasmodium falciparum sporozoites , 2022, Nature.
[3] A. Pain,et al. Creation and preclinical evaluation of genetically attenuated malaria parasites arresting growth late in the liver , 2022, npj Vaccines.
[4] J. Kublin,et al. A genetically engineered Plasmodium falciparum parasite vaccine provides protection from controlled human malaria infection , 2022, Science Translational Medicine.
[5] S. Hoffman,et al. A PfSPZ vaccine immunization regimen equally protective against homologous and heterologous controlled human malaria infection , 2022, NPJ vaccines.
[6] G. E. Potter,et al. PfSPZ-CVac malaria vaccine demonstrates safety among malaria-experienced adults: A randomized, controlled phase 1 trial , 2022, EClinicalMedicine.
[7] Joana C. Silva,et al. Plasmodium falciparum 7G8 challenge provides conservative prediction of efficacy of PfNF54-based PfSPZ Vaccine in Africa , 2022, Nature Communications.
[8] S. Hoffman,et al. Efficacy, T cell activation and antibody responses in accelerated Plasmodium falciparum sporozoite chemoprophylaxis vaccine regimens , 2022, NPJ vaccines.
[9] S. Hoffman,et al. Cryopreserved Sporozoites with and without the Glycolipid Adjuvant 7DW8-5 Protect in Prime-and-Trap Malaria Vaccination. , 2022, The American journal of tropical medicine and hygiene.
[10] S. Hoffman,et al. Multi-Dose Priming Regimens of PfSPZ Vaccine: Safety and Efficacy against Controlled Human Malaria Infection in Equatoguinean Adults , 2022, The American journal of tropical medicine and hygiene.
[11] S. Hoffman,et al. Cryopreservation of Anopheles stephensi embryos , 2022, Scientific reports.
[12] I. M. Gandidi,et al. Vaccine cold chain management and cold storage technology to address the challenges of vaccination programs , 2021, Energy Reports.
[13] M. Tshimanga,et al. Factors associated with a malaria outbreak at Tongogara refugee camp in Chipinge District, Zimbabwe, 2021: a case–control study , 2021, Malaria journal.
[14] S. Kappe,et al. Malaria parasite liver stages. , 2021, Journal of hepatology.
[15] G. E. Potter,et al. Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial , 2021, Nature Medicine.
[16] P. Njuguna,et al. Safety and PCR monitoring in 161 semi-immune Kenyan adults following controlled human malaria infection , 2021, JCI insight.
[17] A. Vaughan,et al. Plasmodium vivax Latent Liver Stage Infection and Relapse: Biological Insights and New Experimental Tools. , 2021, Annual review of microbiology.
[18] S. Hoffman,et al. Two chemoattenuated PfSPZ malaria vaccines induce sterile hepatic immunity , 2021, Nature.
[19] U. d’Alessandro,et al. Efficacy, Safety and Tolerability of Pyronaridine-artesunate in Asymptomatic Malaria-infected Individuals: a Randomized Controlled Trial , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[20] S. Hoffman,et al. Heterologous protection against malaria by a simple chemoattenuated PfSPZ vaccine regimen in a randomized trial , 2021, Nature Communications.
[21] S. Hoffman,et al. PfSPZ-CVac efficacy against malaria increases from 0% to 75% when administered in the absence of erythrocyte stage parasitemia: A randomized, placebo-controlled trial with controlled human malaria infection , 2021, PLoS pathogens.
[22] Erika L. Flannery,et al. Partial protection against P. vivax infection diminishes hypnozoite burden and blood-stage relapses. , 2021, Cell host & microbe.
[23] E. James. Disrupting vaccine logistics , 2021, International health.
[24] B. Gamain,et al. Progress and Insights Toward an Effective Placental Malaria Vaccine , 2021, Frontiers in Immunology.
[25] P. Duffy. Transmission-Blocking Vaccines: Harnessing Herd Immunity for Malaria Elimination , 2021, Expert review of vaccines.
[26] S. Hoffman,et al. Immunogenicity and Protective Efficacy of Radiation-Attenuated and Chemo-Attenuated PfSPZ Vaccines in Equatoguinean Adults , 2020, The American journal of tropical medicine and hygiene.
[27] Andrea A. Berry,et al. Multidose Priming and Delayed Boosting Improve PfSPZ Vaccine Efficacy against Heterologous P. falciparum Controlled Human Malaria Infection. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[28] K. Matuschewski,et al. Low immunogenicity of malaria pre‐erythrocytic stages can be overcome by vaccination , 2020, bioRxiv.
[29] B. Everts,et al. Plasmodium sporozoites induce regulatory macrophages , 2020, PLoS pathogens.
[30] D. Lauffenburger,et al. Mapping functional humoral correlates of protection against malaria challenge following RTS,S/AS01 vaccination , 2020, Science Translational Medicine.
[31] Linda A. Murray,et al. A Phase IIa Controlled Human Malaria Infection and Immunogenicity Study of RTS,S/AS01E and RTS,S/AS01B Delayed Fractional Dose Regimens in Malaria-Naive Adults , 2020, The Journal of infectious diseases.
[32] S. Hoffman,et al. Caregiver and community perceptions and experiences participating in an infant malaria prevention trial of PfSPZ Vaccine administered by direct venous inoculation: a qualitative study in Siaya County, western Kenya , 2020, Malaria Journal.
[33] A. Vaughan,et al. A replication-competent late liver stage-attenuated human malaria parasite. , 2020, JCI insight.
[34] L. Coffeng,et al. An open-label phase 1/2a trial of a genetically modified rodent malaria parasite for immunization against Plasmodium falciparum malaria , 2020, Science Translational Medicine.
[35] S. Hoffman,et al. A double-blind, placebo-controlled phase 1/2a trial of the genetically attenuated malaria vaccine PfSPZ-GA1 , 2020, Science Translational Medicine.
[36] S. Hoffman,et al. Feasibility of direct venous inoculation of the radiation-attenuated Plasmodium falciparum whole sporozoite vaccine in children and infants in Siaya, western Kenya. , 2020, Vaccine.
[37] F. Wamunyokoli,et al. Diversity and Multiplicity of P. falciparum infections among asymptomatic school children in Mbita, Western Kenya , 2020, Scientific Reports.
[38] C. Jackson,et al. Avid binding by B cells to the Plasmodium circumsporozoite protein repeat suppresses responses to protective subdominant epitopes , 2020, bioRxiv.
[39] M. Wadsworth,et al. Prevention of tuberculosis in macaques after intravenous BCG immunization , 2020, Nature.
[40] J. Harty,et al. You Shall Not Pass: Memory CD8 T Cells in Liver-Stage Malaria. , 2019, Trends in parasitology.
[41] R. Sauerwein,et al. Activatory Receptor NKp30 Predicts NK Cell Activation During Controlled Human Malaria Infection , 2019, Front. Immunol..
[42] S. Hoffman,et al. Increase of dose associated with decrease in protection against controlled human malaria infection by PfSPZ Vaccine in Tanzanian adults. , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[43] J. Kublin,et al. Chemoprophylaxis vaccination: Phase 1 study to explore stage-specific immunity to Plasmodium falciparum in U.S. adults. , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[44] R. Sauerwein,et al. Fast and fierce versus slow and smooth: Heterogeneity in immune responses to Plasmodium in the controlled human malaria infection model , 2019, Immunological reviews.
[45] S. Hoffman,et al. Controlled human malaria infection of healthy lifelong malaria-exposed adults to assess safety, immunogenicity and efficacy of the asexual blood stage malaria vaccine candidate GMZ2. , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[46] G. E. Potter,et al. Dose dependent infectivity of aseptic, purified, cryopreserved Plasmodium falciparum 7G8 sporozoites in malaria-naive adults. , 2019, The Journal of infectious diseases.
[47] S. Hoffman,et al. Serologic Markers of Previous Malaria Exposure and Functional Antibodies Inhibiting Parasite Growth Are Associated With Parasite Kinetics Following a Plasmodium falciparum Controlled Human Infection , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[48] James B. Munro,et al. Strains used in whole organism Plasmodium falciparum vaccine trials differ in genome structure, sequence, and immunogenic potential , 2019, Genome Medicine.
[49] S. Hoffman,et al. Safety and Differential Antibody and T-Cell Responses to the Plasmodium falciparum Sporozoite Malaria Vaccine, PfSPZ Vaccine, by Age in Tanzanian Adults, Adolescents, Children, and Infants , 2019, The American journal of tropical medicine and hygiene.
[50] R. Sauerwein,et al. Can Patrolling Liver-Resident T Cells Control Human Malaria Parasite Development? , 2019, Trends in immunology.
[51] M. Netea,et al. Outcomes of controlled human malaria infection after BCG vaccination , 2019, Nature Communications.
[52] M. Schmid,et al. Transcriptome analysis of Plasmodium berghei during exo-erythrocytic development , 2019, Malaria Journal.
[53] S. Hoffman,et al. Malaria vaccine trials in pregnant women: An imperative without precedent. , 2019, Vaccine.
[54] S. Kappe,et al. Designer Parasites: Genetically Engineered Plasmodium as Vaccines To Prevent Malaria Infection , 2019, The Journal of Immunology.
[55] P. Njuguna,et al. Controlled Human Malaria Infection in Semi-Immune Kenyan Adults (CHMI-SIKA): a study protocol to investigate in vivo Plasmodium falciparum malaria parasite growth in the context of pre-existing immunity , 2018, Wellcome open research.
[56] M. Mamani-Matsuda,et al. Human Vγ9Vδ2 T Lymphocytes in the Immune Response to P. falciparum Infection , 2018, Front. Immunol..
[57] S. Thiberge,et al. Cytotoxic anti-circumsporozoite antibodies target malaria sporozoites in the host skin , 2018, Nature Microbiology.
[58] Joana C. Silva,et al. A Plasmodium berghei sporozoite-based vaccination platform against human malaria , 2018, npj Vaccines.
[59] S. Murphy,et al. Prime-and-Trap Malaria Vaccination To Generate Protective CD8+ Liver-Resident Memory T Cells , 2018, The Journal of Immunology.
[60] S. Hoffman,et al. Safety, Immunogenicity, and Protective Efficacy against Controlled Human Malaria Infection of Plasmodium falciparum Sporozoite Vaccine in Tanzanian Adults , 2018, The American journal of tropical medicine and hygiene.
[61] S. Hoffman,et al. Antihomotypic affinity maturation improves human B cell responses against a repetitive epitope , 2018, Science.
[62] R. Saya,et al. Immunization with one Theileria parva strain results in similar level of CTL strain-specificity and protection compared to immunization with the three-component Muguga cocktail in MHC-matched animals , 2018, BMC Veterinary Research.
[63] Erika L. Flannery,et al. Immunization of Malaria-Preexposed Volunteers With PfSPZ Vaccine Elicits Long-Lived IgM Invasion-Inhibitory and Complement-Fixing Antibodies , 2018, The Journal of infectious diseases.
[64] J. Kublin,et al. A Randomized Trial Evaluating the Prophylactic Activity of DSM265 Against Preerythrocytic Plasmodium falciparum Infection During Controlled Human Malarial Infection by Mosquito Bites and Direct Venous Inoculation , 2018, The Journal of infectious diseases.
[65] S. Hoffman,et al. A public antibody lineage that potently inhibits malaria infection by dual binding to the circumsporozoite protein , 2018, Nature Medicine.
[66] S. Hoffman,et al. Impact of Sickle Cell Trait and Naturally Acquired Immunity on Uncomplicated Malaria after Controlled Human Malaria Infection in Adults in Gabon , 2017, The American journal of tropical medicine and hygiene.
[67] T. Horii,et al. Immune evasion of Plasmodium falciparum by RIFIN via inhibitory receptors , 2017, Nature.
[68] S. Hoffman,et al. Advancing Global Health through Development and Clinical Trials Partnerships: A Randomized, Placebo-Controlled, Double-Blind Assessment of Safety, Tolerability, and Immunogenicity of PfSPZ Vaccine for Malaria in Healthy Equatoguinean Men , 2017, The American journal of tropical medicine and hygiene.
[69] S. Hoffman,et al. γδ T Cells Are Required for the Induction of Sterile Immunity during Irradiated Sporozoite Vaccinations , 2017, The Journal of Immunology.
[70] M. Huynen,et al. Modest heterologous protection after Plasmodium falciparum sporozoite immunization: a double-blind randomized controlled clinical trial , 2017, BMC Medicine.
[71] C. Janse,et al. Protective immunity differs between routes of administration of attenuated malaria parasites independent of parasite liver load , 2017, Scientific Reports.
[72] A. Vaughan,et al. Genetically attenuated malaria parasites as vaccines , 2017, Expert review of vaccines.
[73] A. Vaughan,et al. Malaria Parasite Liver Infection and Exoerythrocytic Biology. , 2017, Cold Spring Harbor perspectives in medicine.
[74] K. Matuschewski,et al. Engineering of Genetically Arrested Parasites (GAPs) For a Precision Malaria Vaccine , 2017, Front. Cell. Infect. Microbiol..
[75] C. Janse,et al. The use of transgenic parasites in malaria vaccine research , 2017, Expert review of vaccines.
[76] D. Pratt,et al. Role of controlled human malaria infection (CHMI) in malaria vaccine development: A U.S. food & drug administration (FDA) perspective. , 2017, Vaccine.
[77] R. Germain,et al. Prime and target immunization protects against liver-stage malaria in mice , 2018, Science Translational Medicine.
[78] F. Frischknecht,et al. Plasmodium Sporozoite Biology. , 2017, Cold Spring Harbor perspectives in medicine.
[79] Sumana Chakravarty,et al. Sterile protection against human malaria by chemoattenuated PfSPZ vaccine , 2017, Nature.
[80] Sumana Chakravarty,et al. Protection against Plasmodium falciparum malaria by PfSPZ Vaccine. , 2017, JCI insight.
[81] J. Kublin,et al. Complete attenuation of genetically engineered Plasmodium falciparum sporozoites in human subjects , 2017, Science Translational Medicine.
[82] Scott N. Mueller,et al. Liver-Resident Memory CD8+ T Cells Form a Front-Line Defense against Malaria Liver-Stage Infection. , 2016, Immunity.
[83] T. Richie,et al. Protective Efficacy of Plasmodium vivax Radiation-Attenuated Sporozoites in Colombian Volunteers: A Randomized Controlled Trial , 2016, PLoS neglected tropical diseases.
[84] Paige E. Waterman,et al. Fractional Third and Fourth Dose of RTS,S/AS01 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection and Immunogenicity Study. , 2016, The Journal of infectious diseases.
[85] S. Hoffman,et al. Mosquito bite immunization with radiation-attenuated Plasmodium falciparum sporozoites: safety, tolerability, protective efficacy and humoral immunogenicity , 2016, Malaria Journal.
[86] Mario Roederer,et al. Protection against malaria at 1 year and immune correlates following PfSPZ vaccination , 2016, Nature Medicine.
[87] S. Hoffman,et al. Safety, Immunogenicity, and Protective Efficacy of Intradermal Immunization with Aseptic, Purified, Cryopreserved Plasmodium falciparum Sporozoites in Volunteers under Chloroquine Prophylaxis: A Randomized Controlled Trial , 2016, The American journal of tropical medicine and hygiene.
[88] A. McMichael,et al. Evolution of the immune system in humans from infancy to old age , 2015, Proceedings of the Royal Society B: Biological Sciences.
[89] S. Hoffman,et al. Optimizing Intradermal Administration of Cryopreserved Plasmodium falciparum Sporozoites in Controlled Human Malaria Infection , 2015, The American journal of tropical medicine and hygiene.
[90] M. Fried,et al. Designing a VAR2CSA-based vaccine to prevent placental malaria✩ , 2015, Vaccine.
[91] A. Barry,et al. Designing malaria vaccines to circumvent antigen variability , 2015, Vaccine.
[92] Q. Bassat,et al. Strategies for Understanding and Reducing the Plasmodium vivax and Plasmodium ovale Hypnozoite Reservoir in Papua New Guinean Children: A Randomised Placebo-Controlled Trial and Mathematical Model , 2015, PLoS medicine.
[93] S. Hoffman,et al. Discovery of Novel Plasmodium falciparum Pre-Erythrocytic Antigens for Vaccine Development , 2015, PloS one.
[94] S. Hoffman,et al. Controlled human malaria infection by intramuscular and direct venous inoculation of cryopreserved Plasmodium falciparum sporozoites in malaria-naïve volunteers: effect of injection volume and dose on infectivity rates , 2015, Malaria Journal.
[95] G. van Gemert,et al. Heterologous Protection against Malaria after Immunization with Plasmodium falciparum Sporozoites , 2015, PloS one.
[96] A. Vaughan,et al. Mechanisms of Stage-Transcending Protection Following Immunization of Mice with Late Liver Stage-Arresting Genetically Attenuated Malaria Parasites , 2015, PLoS pathogens.
[97] Charles C. Kim,et al. FCRL5 Delineates Functionally Impaired Memory B Cells Associated with Plasmodium falciparum Exposure , 2015, PLoS pathogens.
[98] S. Hoffman,et al. Direct venous inoculation of Plasmodium falciparum sporozoites for controlled human malaria infection: a dose-finding trial in two centres , 2015, Malaria Journal.
[99] S. Hoffman,et al. Increased sample volume and use of quantitative reverse-transcription PCR can improve prediction of liver-to-blood inoculum size in controlled human malaria infection studies , 2015, Malaria Journal.
[100] G. van Gemert,et al. Sporozoite Immunization of Human Volunteers under Mefloquine Prophylaxis Is Safe, Immunogenic and Protective: A Double-Blind Randomized Controlled Clinical Trial , 2014, PloS one.
[101] S. Hoffman,et al. Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered by intramuscular injection , 2014, Front. Microbiol..
[102] S. Hoffman,et al. Controlled Human Malaria Infection of Tanzanians by Intradermal Injection of Aseptic, Purified, Cryopreserved Plasmodium falciparum Sporozoites , 2014, The American journal of tropical medicine and hygiene.
[103] S. Kappe,et al. A next-generation genetically attenuated Plasmodium falciparum parasite created by triple gene deletion. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.
[104] Samuel A. Assefa,et al. A barcode of organellar genome polymorphisms identifies the geographic origin of Plasmodium falciparum strains , 2014, Nature Communications.
[105] G. van Gemert,et al. Cytotoxic Markers Associate With Protection Against Malaria in Human Volunteers Immunized With Plasmodium falciparum Sporozoites , 2014, The Journal of infectious diseases.
[106] S. Hoffman,et al. Two Plasmodium 6‐Cys family‐related proteins have distinct and critical roles in liver‐stage development , 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[107] R. Ahmed,et al. PD-1 dependent exhaustion of CD8+ T cells drives chronic malaria. , 2013, Cell reports.
[108] S. Kappe,et al. First-in-human evaluation of genetically attenuated Plasmodium falciparum sporozoites administered by bite of Anopheles mosquitoes to adult volunteers. , 2013, Vaccine.
[109] E. Gotuzzo,et al. Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years. , 2013, The American journal of tropical medicine and hygiene.
[110] E. Hempelmann,et al. Bad air, amulets and mosquitoes: 2,000 years of changing perspectives on malaria , 2013, Malaria Journal.
[111] S. Hoffman,et al. Optimising Controlled Human Malaria Infection Studies Using Cryopreserved P. falciparum Parasites Administered by Needle and Syringe , 2013, PloS one.
[112] Bjoern Peters,et al. Identification of minimal human MHC-restricted CD8+ T-cell epitopes within the Plasmodium falciparum circumsporozoite protein (CSP) , 2013, Malaria Journal.
[113] R. Sauerwein,et al. Liver or blood-stage arrest during malaria sporozoite immunization: the later the better? , 2013, Trends in parasitology.
[114] S. Dalai,et al. The Survival of Memory CD8 T Cells That Is Mediated by IL-15 Correlates with Sustained Protection Against Malaria , 2013, The Journal of Immunology.
[115] A. Scott,et al. Unique transcriptional profile of liver-resident memory CD8+ T cells induced by immunization with malaria sporozoites , 2013, Genes and Immunity.
[116] M. Bevan,et al. A T-cell response to a liver-stage Plasmodium antigen is not boosted by repeated sporozoite immunizations , 2013, Proceedings of the National Academy of Sciences.
[117] D. Carucci,et al. DNA Prime/Adenovirus Boost Malaria Vaccine Encoding P. falciparum CSP and AMA1 Induces Sterile Protection Associated with Cell-Mediated Immunity , 2013, PloS one.
[118] Peter D. Crompton,et al. Chronic Exposure to Plasmodium falciparum Is Associated with Phenotypic Evidence of B and T Cell Exhaustion , 2013, The Journal of Immunology.
[119] S. Hoffman,et al. Controlled Human Malaria Infections by Intradermal Injection of Cryopreserved Plasmodium falciparum Sporozoites , 2013, The American journal of tropical medicine and hygiene.
[120] S. Hoffman,et al. Comparative cost models of a liquid nitrogen vapor phase (LNVP) cold chain-distributed cryopreserved malaria vaccine vs. a conventional vaccine. , 2013, Vaccine.
[121] P. Brey,et al. Visualizing Non Infectious and Infectious Anopheles gambiae Blood Feedings in Naive and Saliva-Immunized Mice , 2012, PloS one.
[122] Q. Bassat,et al. Relapses contribute significantly to the risk of Plasmodium vivax infection and disease in Papua New Guinean children 1-5 years of age. , 2012, The Journal of infectious diseases.
[123] S. Hoffman,et al. Clinical trial in healthy malaria-naïve adults to evaluate the safety, tolerability, immunogenicity and efficacy of MuStDO5, a five-gene, sporozoite/hepatic stage Plasmodium falciparum DNA vaccine combined with escalating dose human GM-CSF DNA , 2012, Human vaccines & immunotherapeutics.
[124] S. Dalai,et al. Memory CD8 T Cells Specific for Plasmodia Liver-Stage Antigens Maintain Protracted Protection Against Malaria , 2012, Front. Immun..
[125] M. Miyakoda,et al. The species specificity of immunity generated by live whole organism immunisation with erythrocytic and pre-erythrocytic stages of rodent malaria parasites and implications for vaccine development. , 2012, International journal for parasitology.
[126] K. Marsh,et al. Naturally acquired immune responses against Plasmodium falciparum sporozoites and liver infection. , 2012, International journal for parasitology.
[127] O. Doumbo,et al. Next generation sequencing to detect variation in the Plasmodium falciparum circumsporozoite protein. , 2012, The American journal of tropical medicine and hygiene.
[128] D. L. Guilbride,et al. Malaria's deadly secret: a skin stage. , 2012, Trends in parasitology.
[129] W. Weiss,et al. Protective CD8+ T lymphocytes in Primates Immunized with Malaria Sporozoites , 2012, PloS one.
[130] R. Sauerwein,et al. Longevity and Composition of Cellular Immune Responses Following Experimental Plasmodium falciparum Malaria Infection in Humans , 2011, PLoS pathogens.
[131] E. R. James,et al. Live Attenuated Malaria Vaccine Designed to Protect Through Hepatic CD8+ T Cell Immunity , 2011, Science.
[132] N. White. Determinants of relapse periodicity in Plasmodium vivax malaria , 2011, Malaria Journal.
[133] D. Carucci,et al. Adenovirus 5-Vectored P. falciparum Vaccine Expressing CSP and AMA1. Part A: Safety and Immunogenicity in Seronegative Adults , 2011, PloS one.
[134] D. Carucci,et al. Adenovirus-5-Vectored P. falciparum Vaccine Expressing CSP and AMA1. Part B: Safety, Immunogenicity and Protective Efficacy of the CSP Component , 2011, PloS one.
[135] A. Vaughan,et al. Superior antimalarial immunity after vaccination with late liver stage-arresting genetically attenuated parasites. , 2011, Cell host & microbe.
[136] J. Sacci,et al. Identification of two new protective pre-erythrocytic malaria vaccine antigen candidates , 2011, Malaria Journal.
[137] S. Hoffman,et al. Immune responses and protection of Aotus monkeys immunized with irradiated Plasmodium vivax sporozoites. , 2011, The American journal of tropical medicine and hygiene.
[138] F. Zavala,et al. CD4+ T Cells Modulate Expansion and Survival but Not Functional Properties of Effector and Memory CD8+ T Cells Induced by Malaria Sporozoites , 2011, PloS one.
[139] S. Thiberge,et al. Development of the malaria parasite in the skin of the mammalian host , 2010, Proceedings of the National Academy of Sciences.
[140] Bjoern Peters,et al. Identification and localization of minimal MHC-restricted CD8+ T cell epitopes within the Plasmodium falciparum AMA1 protein , 2010, Malaria Journal.
[141] K. Matuschewski,et al. Natural Immunization Against Malaria: Causal Prophylaxis with Antibiotics , 2010, Science Translational Medicine.
[142] Sumana Chakravarty,et al. Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria , 2010, Human vaccines.
[143] S. Hoffman,et al. The potential role of vaccines in the elimination of falciparum malaria and the eventual eradication of malaria. , 2009, The Journal of infectious diseases.
[144] S. Kappe,et al. Genetically Attenuated Parasite Vaccines Induce Contact-Dependent CD8+ T Cell Killing of Plasmodium yoelii Liver Stage-Infected Hepatocytes1 , 2009, The Journal of Immunology.
[145] A. Aly,et al. Preerythrocytic, live-attenuated Plasmodium falciparum vaccine candidates by design , 2009, Proceedings of the National Academy of Sciences.
[146] C. Rogier,et al. Assessment of the relative success of sporozoite inoculations in individuals exposed to moderate seasonal transmission , 2009, Malaria Journal.
[147] T. Richie,et al. Immune evasion by malaria parasites: a challenge for vaccine development. , 2009, Current opinion in immunology.
[148] R. Price,et al. Parasite-Dependent Expansion of TNF Receptor II–Positive Regulatory T Cells with Enhanced Suppressive Activity in Adults with Severe Malaria , 2009, PLoS pathogens.
[149] G. Di Giulio,et al. Live immunization against East Coast fever--current status. , 2009, Trends in parasitology.
[150] S. Hoffman,et al. Gene Disruption of Plasmodium falciparum p52 Results in Attenuation of Malaria Liver Stage Development in Cultured Primary Human Hepatocytes , 2008, PloS one.
[151] U. Frevert,et al. Cellular effector mechanisms against Plasmodium liver stages , 2008, Cellular microbiology.
[152] K. Matuschewski,et al. A Sporozoite Asparagine-Rich Protein Controls Initiation of Plasmodium Liver Stage Development , 2008, PLoS pathogens.
[153] I. Coppens,et al. Targeted deletion of SAP1 abolishes the expression of infectivity factors necessary for successful malaria parasite liver infection , 2008, Molecular microbiology.
[154] Xinxia Peng,et al. A combined transcriptome and proteome survey of malaria parasite liver stages , 2008, Proceedings of the National Academy of Sciences.
[155] M. Mota,et al. Genetically attenuated P36p-deficient Plasmodium berghei sporozoites confer long-lasting and partial cross-species protection. , 2007, International journal for parasitology.
[156] S. Hoffman,et al. Cross-protection between attenuated Plasmodium berghei and P. yoelii sporozoites , 2007, Parasite immunology.
[157] J. Sacci,et al. CD8+ T lymphocytes protective against malaria liver stages are primed in skin-draining lymph nodes , 2007, Nature Medicine.
[158] A. Cowman,et al. Plasmodium falciparum erythrocyte membrane protein-1 specifically suppresses early production of host interferon-gamma. , 2007, Cell host & microbe.
[159] S. Kappe,et al. Protracted sterile protection with Plasmodium yoelii pre-erythrocytic genetically attenuated parasite malaria vaccines is independent of significant liver-stage persistence and is mediated by CD8+ T cells. , 2007, The Journal of infectious diseases.
[160] S. Kappe,et al. Genetically attenuated Plasmodium berghei liver stages induce sterile protracted protection that is mediated by major histocompatibility complex Class I-dependent interferon-gamma-producing CD8+ T cells. , 2007, The Journal of infectious diseases.
[161] Michelle M. Garrison,et al. Freezing temperatures in the vaccine cold chain: a systematic literature review. , 2007, Vaccine.
[162] J. Kublin,et al. Dual Infection with HIV and Malaria Fuels the Spread of Both Diseases in Sub-Saharan Africa , 2006, Science.
[163] T. J. Templeton,et al. Variant antigen gene expression in malaria , 2006, Cellular microbiology.
[164] M. Plebanski,et al. Dimorphic Plasmodium falciparum merozoite surface protein‐1 epitopes turn off memory T cells and interfere with T cell priming , 2006, European journal of immunology.
[165] S. Shorte,et al. Quantitative imaging of Plasmodium transmission from mosquito to mammal , 2006, Nature Medicine.
[166] Y. Chinzei,et al. Two proteins with 6‐cys motifs are required for malarial parasites to commit to infection of the hepatocyte , 2005, Molecular microbiology.
[167] R. Sinden,et al. Upregulation of TGF-beta, FOXP3, and CD4+CD25+ regulatory T cells correlates with more rapid parasite growth in human malaria infection. , 2005, Immunity.
[168] M. Mota,et al. Genetically attenuated, P36p-deficient malarial sporozoites induce protective immunity and apoptosis of infected liver cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[169] N. Steers,et al. The immune status of Kupffer cells profoundly influences their responses to infectious Plasmodium berghei sporozoites , 2005, European journal of immunology.
[170] S. Kappe,et al. Plasmodium liver stage developmental arrest by depletion of a protein at the parasite-host interface. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[171] S. Kappe,et al. Genetically modified Plasmodium parasites as a protective experimental malaria vaccine , 2005, Nature.
[172] O. Skorokhod,et al. Hemozoin (Malarial Pigment) Inhibits Differentiation and Maturation of Human Monocyte-Derived Dendritic Cells: A Peroxisome Proliferator-Activated Receptor-γ-Mediated Effect1 , 2004, The Journal of Immunology.
[173] S. Hoffman,et al. Safety, tolerability, and antibody responses in humans after sequential immunization with a PfCSP DNA vaccine followed by the recombinant protein vaccine RTS,S/AS02A. , 2004, Vaccine.
[174] L. Rénia,et al. Protective T Cell Immunity against Malaria Liver Stage after Vaccination with Live Sporozoites under Chloroquine Treatment 1 , 2004, The Journal of Immunology.
[175] S. Hoffman,et al. Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine , 2003, Journal of Experimental Biology.
[176] Jackie Williams,et al. Protracted Protection to Plasmodium berghei Malaria Is Linked to Functionally and Phenotypically Heterogeneous Liver Memory CD8+ T Cells1 , 2003, The Journal of Immunology.
[177] John Sidney,et al. Identification of Plasmodium falciparum antigens by antigenic analysis of genomic and proteomic data , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[178] Ana Rodriguez,et al. Malaria Blood Stage Suppression of Liver Stage Immunity by Dendritic Cells , 2003, The Journal of experimental medicine.
[179] Jonathan E. Allen,et al. Genome sequence of the human malaria parasite Plasmodium falciparum , 2002, Nature.
[180] Patricia De la Vega,et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. , 2002, The Journal of infectious diseases.
[181] A. Kelso,et al. The Mechanism and Significance of Deletion of Parasite-specific CD4+ T Cells in Malaria Infection , 2002, The Journal of experimental medicine.
[182] S. Hoffman,et al. Incidence of symptomatic and asymptomatic Plasmodium falciparum infection following curative therapy in adult residents of northern Ghana. , 2001, The American journal of tropical medicine and hygiene.
[183] S. Hoffman,et al. The Complexity of Protective Immunity Against Liver-Stage Malaria1 2 , 2000, The Journal of Immunology.
[184] P. De Baetselier,et al. Hemozoin is a key factor in the induction of malaria‐associated immunosuppression , 1999, Parasite immunology.
[185] S. Hoffman,et al. IL-12 and NK cells are required for antigen-specific adaptive immunity against malaria initiated by CD8+ T cells in the Plasmodium yoelii model. , 1999, Journal of immunology.
[186] S. Hoffman,et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. , 1998, Science.
[187] S. Hoffman,et al. Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[188] A. Holder,et al. Characterization of human T- and B-cell epitopes in the C terminus of Plasmodium falciparum merozoite surface protein 1: evidence for poor T-cell recognition of polypeptides with numerous disulfide bonds , 1997, Infection and immunity.
[189] S. Hoffman,et al. Irradiated sporozoite vaccine induces HLA-B8-restricted cytotoxic T lymphocyte responses against two overlapping epitopes of the Plasmodium falciparum sporozoite surface protein 2 , 1995, The Journal of experimental medicine.
[190] S. Hoffman,et al. Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[191] S. Hoffman,et al. Complete protection against Plasmodium yoelii by adoptive transfer of a CD8+ cytotoxic T-cell clone recognizing sporozoite surface protein 2 , 1994, Infection and immunity.
[192] B. Sina,et al. Plasmodium falciparum sporozoite immunization protects against Plasmodium berghei sporozoite infection. , 1993, Experimental parasitology.
[193] S. Hoffman,et al. The role of CD4+ T cells in immunity to malaria sporozoites. , 1993, Journal of immunology.
[194] S. Hoffman,et al. A T cell clone directed at the circumsporozoite protein which protects mice against both Plasmodium yoelii and Plasmodium berghei. , 1992, Journal of immunology.
[195] L. Miller,et al. Sporogonic development of a malaria parasite in vitro. , 1992, Science.
[196] P. Romero,et al. CD8+ cytolytic T cell clones derived against the Plasmodium yoelii circumsporozoite protein protect against malaria. , 1991, International immunology.
[197] S. Hoffman,et al. Human cytotoxic T lymphocytes against the Plasmodium falciparum circumsporozoite protein. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[198] S. Hoffman,et al. Cytotoxic T cells recognize a peptide from the circumsporozoite protein on malaria-infected hepatocytes , 1990, The Journal of experimental medicine.
[199] V. Nussenzweig,et al. Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria , 1989, Nature.
[200] S. Hoffman,et al. Sporozoite vaccine induces genetically restricted T cell elimination of malaria from hepatocytes. , 1989, Science.
[201] V. Nussenzweig,et al. γ Interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites , 1987, Nature.
[202] S. Hoffman,et al. Naturally acquired antibodies to sporozoites do not prevent malaria: vaccine development implications. , 1987, Science.
[203] H. Webster,et al. Antigen-specific immunosuppression in human malaria due to Plasmodium falciparum. , 1986, The Journal of infectious diseases.
[204] W. Szmuness,et al. Hepatitis B vaccine administered to chronic carriers of hepatitis b surface antigen. , 1982, Annals of internal medicine.
[205] R. Beaudoin,et al. Plasmodium berghei: immunization of mice against the ANKA strain using the unaltered sporozoite as an antigen. , 1977, Experimental parasitology.
[206] D. Clyde,et al. Plasmodium vivax: correlation of circumsporozoite precipitation (CSP) reaction with sporozoite-induced protective immunity in man. , 1977, Experimental parasitology.
[207] D. Clyde,et al. Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites. , 1975, The American journal of tropical medicine and hygiene.
[208] R. Miller,et al. Specificity of protection of man immunized against sporozoite‐induced falciparum malaria , 1973, The American journal of the medical sciences.
[209] J. Vanderberg,et al. Immunization of man against sporozite-induced falciparum malaria , 1973, The American journal of the medical sciences.
[210] J. Vanderberg,et al. Sporozoite-induced immunity in mammalian malaria. A review. , 1972, The American journal of tropical medicine and hygiene.
[211] W. Collins,et al. Immunization of monkeys against Plasmodium cynomolgi by X-irradiated sporozoites. , 1972, Nature: New biology.
[212] J. Vanderberg,et al. Protective Immunity produced by the Injection of X-irradiated Sporozoites of Plasmodium berghei , 1967, Nature.
[213] W. Richards. Active Immunization of Chicks against Plasmodium gallinaceum by Inactivated Homologous Sporozoites and Erythrocytic Parasites , 1966, Nature.
[214] I. McGregor,et al. Antibody response to tetanus toxoid inoculation in malarious and non-malarious Gambian children , 1962 .
[215] J. Freund,et al. IMMUNIZATION OF RHESUS MONKEYS AGAINST MALARIAL INFECTION (P. KNOWLESI) WITH KILLED PARASITES AND ADJUVANTS. , 1945, Science.
[216] J. Freund,et al. IMMUNIZATION AGAINST MALARIA: VACCINATION OF DUCKS WITH KILLED PARASITES INCORPORATED WITH ADJUVANTS , 1945, Science.
[217] P. F. Russell,et al. THE IMMUNIZATION OF FOWLS AGAINST MOSQUITO-BORNE PLASMODIUM GALLINACEUM BY INJECTIONS OF SERUM AND OF INACTIVATED HOMOLOGOUS SPOROZOITES , 1942, The Journal of experimental medicine.
[218] Alex B. Miller,et al. A human monoclonal antibody prevents malaria infection and defines a new site of vulnerability on Plasmodium falciparum circumsporozoite protein , 2018 .
[219] M. Good,et al. CD8+ T cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[220] T. Burkot,et al. Infectivity to mosquitoes of Plasmodium falciparum clones grown in vitro from the same isolate. , 1984, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[221] R. Nussenzweig,et al. Comparative studies on the immunogenicity of infective and attenuated sporozoites of Plasmodium berghei. , 1982, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[222] K. Sell,et al. Letter: Sporozoite induced immunity in man against an Ethiopian strain of Plasmodium falciparum. , 1974, Transactions of the Royal Society of Tropical Medicine and Hygiene.